Thrombotic thrombocytopenic purpura is a syndrome characterized by hemolytic anemia, thrombocytopenia, neurological symptoms, fever and renal dysfunction. Although the syndrome is usually associated with various infections, vasculitis and pregnancy, rarely can it be associated with certain neoplasms and drugs such as ticlopidine. A 63-year-old woman, who had undergone coronary angioplasty and had been started on ticlopidine, was admitted to our clinic with a history of vomiting, fatigue, hematuria and deterioration in her cognitive abilities. Thrombotic thrombocytopenic purpura was diagnosed on the basis of neurological changes, an increase in LDH, urea, creatinine, indirect bilirubin levels, anemia and peripheral smear findings. Treatment was initiated with daily plasmapheresis and complete clinical and laboratory recovery developed. The patient was discharged after 14 days.

Bell WR, Braine HG, Ness FM, Kickler TS: Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991;325:398–403.
Rose M, Rowe JM, Eldor A: The changing course of thrombotic thrombocytopenic purpura. Blood Rev 1993;7:94–103.
Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325:393–397.
Torok TJ, Holman RC, Chorba TL: Increasing mortality from thrombotic thrombocytopenic purpura in the United States – Analysis of national mortality data, 1968–1991. Am J Hematol 1995;50:84–90.
Rose M, Eldor A: High incidence of relapse in thrombotic thrombocytopenic purpura. Clinical study of 38 patients. Am J Med 1987;83:437–444.
Gordon LI, Kwaan HC: Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997;34:140–147.
Bennett CL, Weinberg PD, Ben-Dror KR, Yarnold PR, Kwaan HC, Green D: Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Intern Med 1998;128:541–544.
Wysowski DK, Bacsanyi J: Blood dyscrasias and hematologic reactions in ticlopidine users (letter). JAMA 1996;276:952.
Kovacs MJ, Soong YP, Chin-Hee IH: Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Pharmacother 1993;27:1060–1061.
Page Y, Tardy B, Zeni F, Comtet C, Terrana R, Bertrand JC: Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991;337:774–776.
Capra R, Marciano N, Finei F, Capucci M, Ferremi P, Orlandini A: Cerebral hemorrhage and thrombotic thrombocytopenic purpura during ticlopidine treatment. Acta Neurol Belg 1992;92:83–87.
Kodama K, Nomura T, Yasui K, Matsuo T: Thrombotic thrombocytopenic purpura after administration of ticlopidine. Case report. Rinsho Ketsueki 1996;37:1334–1336.
Ariyoshi K, Shinohara K, Ruirong X: Thrombotic thrombocytopenic purpura caused by ticlopidine, successfully treated by plasmapheresis (letter). Am J Hematol 1997;54:175–176.
Kupfer Y, Tessler S: Ticlopidine and thrombotic thrombocytopenic purpura (letter). N Engl J Med 1997;337:1245.
Ellie E, Durrieu C, Besse P, Julien J, Gbipki-Benissan G: Thrombotic thrombocytopenic purpura associated with ticlopidine (letter). Stroke 1992;23:922–923.
Haas WK, Easton JD, Adams HP, Pryse-Phillips W, Molony BA, Anderson S, Kamm B: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501–507.
Steinhubl SR, Tan WA, Foody JM, Topol EJ: Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. JAMA 1999;281:806–810.
Page Y, Tardy B, Zeni F, Comtet C, Terrana R, Bertrand JC: Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991;337:774–776.
Moake JL, McPherson PD: Abnormalities of von Willebrand factor multimers in thrombocytopenic purpura and hemolytic-uremic syndrome. Am J Med 1989;87:9–15.
Tsai H-M, Lian EC-Y: Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585–1594.
Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B: von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578–1584.
Tsai HM, Rice L, Sarode R, Chow TW, Moake JL: Antibody inhibitors to von Willebrand (VWF) factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000;132:794–799.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.